n INTRODUCTION P olymyalgia rheumatica (PMR) is a relatively common inflammatory rheumatological disorder of older (>50 years) adults. Classical presenting symptoms include bilateral hip and shoulder girdle pain and stiffness, morning stiffness, raised inflammatory markers [classically elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)] and systemic features such as pyrexia, fatigue and weight loss (1). In the absence of a gold standard diagnostic test, PMR remains a clinical diagnosis. Current guidelines from the British Society for Rheumatology, and others, suggest that a variety of disorders should be excluded prior to making a diagnosis of PMR (2-4). These include other rheumatological conditions (including rheumatoid arthritis and fibromyalgia), endocrine diseases (e.g., hypothyroidism) and neurological conditions (e.g., Parkinson's disease), drug-induced myalgia (e.g., from statin treatment), infection and active cancer. Definitively excluding active cancer can be challenging and although simple screening investigations, such as a chest X-ray, are advocated by guidelines, more complex and invasive investigations are not indicated for all patients. The association between cancer and rheumatic disorders has long been recognised. Racanelli et al. (5) summarise these into three groups. First, patients where a rheumatic disorder is directly triggered by a tumour or its metastases (e.g. leukaemic synovitis); second, patients with an established rheumatic condition who are at increased risk of a specific malignancy [e.g., primary Sjögrens syndrome and lymphoma (6) ]; and third, patients with paraneoplastic diseases. This group arises where an apparently idiopathic rheumatic disease is actually the expression of an occult cancer that becomes clinically evident within a defined timeframe [usually 2 years (7)]. Thus A systematic review of Medline and Embase was conducted from their inception to February 2017. Risk of bias was assessed using the Newcastle-Ottawa tool. Data were extracted regarding the PMR-cancer association, the o n l y was assessed using the Newcastle-Ottawa tool. Data were extracted regarding the PMR-cancer association, the types of cancer associated with PMR and the presentation of PMR patients subsequently diagnosed with cancer.
o n l y types of cancer associated with PMR and the presentation of PMR patients subsequently diagnosed with cancer. Twenty-three full text articles were reviewed from the 1174 unique references identified in the search. Nine o n l y Twenty-three full text articles were reviewed from the 1174 unique references identified in the search. Nine articles were included in the final review. There was some evidence of an association between PMR and cancer o n l y articles were included in the final review. There was some evidence of an association between PMR and cancer in the short-term (first 6 to 12 months after diagnosis), but no evidence of an association after this time. Limited o n l y in the short-term (first 6 to 12 months after diagnosis), but no evidence of an association after this time. Limited evidence suggests that lymphoma, prostate and haematological cancers may be those cancers more commonly o n l y evidence suggests that lymphoma, prostate and haematological cancers may be those cancers more commonly a paraneoplastic syndrome is the term used to describe the clinical or systemic symptoms that are associated with a tumour but not caused by direct invasion of the target tissue. Paraneoplastic syndromes are thought to be caused by an altered immune response, either caused by antibody production (e.g., anti-Hu antibody syndrome and lung cancer, which presents as neuropathies) (8) , aberrant hormone release [e.g., syndrome of inappropriate anti-diuretic hormone secretion, SIADH and lung cancer, leading to headache, weakness and low sodium levels (9)] or abnormal cytokine release such as vascular endothelial growth factor (VEGF) (7) . Studies suggest that up to 8% of patients with cancer may have a paraneoplastic syndrome (9) . Symptoms of a paraneoplastic syndrome can affect any organ system, including haematological (e.g., haemolytic anaemia), cutaneous (e.g., scleroderma, clubbing), vascular (e.g., leucocytoclastic vasculitis, Raynaud's phenomenon) and neurological systems (e.g., neuropathies or encephalomyelitis, stiff-man syndrome) (10) . Common rheumatological manifestations include hypertrophic osteoarthropathy, cancer associated myositis, paraneoplastic polyarthritis, and relapsing seronegative symmetric synovitis with pitting oedema (RS3PE) (6) . However, for less specific symptoms, such as joint pain, establishing whether these are truly paraneoplastic is more controversial. Lortholary et al. (11) define a paraneoplastic syndrome using the following criteria: 1. presence of a cancer; 2. clinical presentation not directly due to the primary tumour or metastases; 3. absence of other non-neoplastic causes; 4. parallel evolution. A paraneoplastic syndrome is considered probable if three criteria were met and possible if one or two criteria were met. For a condition such as PMR, which has no specific diagnostic test, establishing whether there is a true association between PMR and malignancy or whether it is a co-incidental existence of the two conditions is more difficult. Classically symptoms of a paraneoplastic syndrome regress after treatment of the underlying cancer. However, given the often rapid improvement of PMR symptoms with low dose glucocorticoids, proving such temporality is unethical and inappropriate. Given the controversy about whether this represents association or co-incidence, this review will consider the evidence for the association between PMR and cancer. Specifically, it will consider timescales and whether any presenting features were associated with a later diagnosis of cancer to further elucidate the evidence surrounding the paraneoplastic syndrome and PMR (12) .
n MATERIALS AND METHODS

Search strategy
Our search strategy was based on that developed by Ungprasert et al. (13) . The search was conducted in Medline (1946 ( February 2017 and Embase (1974 February 2017 . Full details can be found in the Appendix, but briefly the exploded MeSH term polymyalgia rheumatica was used in combination with text word searches for polymyalgia and PMR. This was combined with searches for the exploded MeSH term neoplasms and text word searches for neoplasm, cancer, malignancy, carcinoma, tumour and other appropriate terms.
Inclusion and exclusion criteria
Inclusion criteria were: 1. cohort study (prospective or retrospective) or randomised controlled trial including an exposed (PMR group) and an unexposed (non-PMR group), or a systematic review; 2. consider the association between a diagnosis of PMR and concomitant or subsequent diagnosis of cancer. Exclusion criteria were: 1. case reports, case series or case-control study; 2. association between PMR and cancer/ paraneoplastic syndrome not considered; 3. no full text article available (e.g., conference abstract), or no English language version of full paper available.
Study selection
Retrieved titles were screened against the inclusion and exclusion criteria by a single The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome REVIEW reviewer (SM). The abstracts of the remaining studies were then examined with studies not meeting the inclusion criteria excluded. Reasons for exclusion were recorded. Finally, full texts of the remaining studies were reviewed and a final list of included studies was prepared (Figure 1 ).
Quality assessment
Assessment of study quality and the likelihood of bias was conducted using the Newcastle-Ottawa scale (14) . This scale uses a star rating so that each study receives a maximum score of four stars for sample selection (whether the sample is representative of the population of interest and how exposure is ascertained), two stars for comparability and three stars for outcome (how outcome was assessed and over what time period). For the purposes of this review, we discounted the comparability section, as it relates to control of potentially confounding factors, which we did not consider relevant to our question regarding an association between PMR and cancer, as we did not require this association to be causal.
Data extraction
Data regarding the following were extracted from each study included in the review:
1. time frame between diagnosis of PMR and diagnosis of cancer; 2. types of cancer associated with PMR; 3. presentation of PMR that was later considered to be cancer, focussing particularly on clinical presenting features (e.g., failure to respond to glucocorticoid treatment); 4. the authors' conclusions as to the nature of any PMR-cancer association.
n RESULTS
Results of the search
A total of 1174 unique citations were obtained (Figure 1 ). 1077 were excluded based on title screening and further 74 were excluded after abstract screening, leaving 23 full articles for review. After this final stage of screening, nine studies remained. The main reasons for exclusion of studies at the abstract and full text screening stages were that articles presented case reports or case series (n=40), that no original data or a systematic review were presented (n=20) or that a full paper was not available in English (n=13).
Articles included in the review
Eight of the nine articles identified through the systematic search described cohort stud- (Table I ) (15) (16) (17) (18) (19) (20) (21) (22) . Two articles utilised the same dataset, but with one considering the outcomes of cancer diagnosis and the other causes of death including cancer (19, 20) . Five of the articles (17) (18) (19) (20) 22) , all from Scandinavia, used an unexposed group taken from a database separate to the PMR group, but representative of the general population, whilst two studies [one from the UK (15), one from the USA (21)] selected an unexposed group from the same clinical source data as the exposed PMR group (Table I) . A final study from Italy selected controls from the same hospital, but with a diagnosis of The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome REVIEW osteoarthritis (16) . All studies used a clinical diagnosis of PMR, ascertained from the medical records, whilst six of the studies also used specified criteria for inclusion (15, 17, (19) (20) (21) (22) . Four of the articles explicitly stated that they did not differentiate PMR from giant cell arteritis (GCA) (17) (18) (19) (20) , one study included only those patients with PMR symptoms and a negative temporal artery biopsy (22) . In the remaining three studies, it was not clear whether those with concomitant GCA were excluded, but all patients were required to have PMR (15, 16, 21 
Which cancers show an association with PMR?
Even the largest studies identified did not have sufficient power to confidently evaluate which cancers were most common in o n l y
Pfeiffer et al. (21) the early stages after a diagnosis of PMR. However, limited evidence suggests that haematological and prostate cancers and lymphoma may be the most commonly diagnosed in those with incident PMR (15, 16, 18) (Table III) .
What evidence is there to identify those with potential paraneoplastic PMR?
There was little evidence provided by the included studies as to the presentation of PMR patients subsequently diagnosed with cancer. However, Bellan et al. (16) 
Author's conclusions as to the nature of the PMR-cancer relationship
The authors of the studies varied in their interpretation of the associations they found between PMR and cancer. Haga et al. (17) and Myklebust et al. (19) considered the average length of time from PMR diagnosis to cancer diagnosis to be too long (greater than three years in both studies), to represent a paraneoplastic phenomenon. Bellan et al. (16) n DISCUSSION
Statement of principal findings
There have been numerous reports in the literature of the co-occurrence of PMR with various malignant diseases. These have highlighted the potential paraneoplastic nature of PMR (23), the chance occurrence of both conditions and the potential for PMR to have a transformative neoplastic effect (24) via an altered immune response (as seen in conditions such as primary Sjögren's syndrome or rheumatoid arthritis), dependent on the time scales involved. Furthermore the condition RS3PE (remitting seronegative symmetrical synovitis with pitting oedema), which has clinical features which overlap with both seronegative rheumatoid arthritis and PMR is considered to be a paraneoplastic rheumatic disease caused by over-production of VEGF (7). Our review found some evidence of a short-term association between PMR and cancer (less than 6 to 12 months after PMR diagnosis). Whilst this raises the possibility of PMR as a paraneoplastic syndrome, definitive evidence is still lacking, given that PMR remains a clinical diagnosis and there is little evidence in the literature that PMR symptoms resolve following cancer treatment. Also, notwithstanding any other diagnoses, the symptoms of PMR may still rapidly improve with low dose glucocorticoids. In patients with RS3PE (which may resemble PMR), the response to glucocorticoids in those with paraneoplastic disease is thought to be poor (25) . In the medium to long term, the evidence regarding an association between PMR and cancer is mixed. The observed association between PMR symptoms and malignancy may represent misdiagnosis of a malignancy as PMR, or coexistence of two conditions in the same individual, either coincidentally, or as result of an underlying susceptibility (e.g., dysregulated immune system). Furthermore there may be some surveillance bias, given that current guidelines suggest that malignancy should be excluded before the diagnosis of PMR can be made (2). This is particularly likely in those studies, where data are taken from routinely collected clinical or registry data, as it is not clear what investigations might or might not have been carried out on the unexposed group. This type of data provides the basis for the vast majority of the studies included in our review. However, the strongest association between PMR and cancer was seen in the study of Bellan et al. (16) The real evidence for polymyalgia rheumatica as a paraneoplastic syndrome REVIEW of people attending a secondary care clinic with a diagnosis of osteoarthritis. Hence, they are likely to also have undergone additional tests, although not necessarily the same ones as those diagnosed with PMR. In the papers included in this review, we were unable to find any convincing evidence of clinical presentations that might be suggestive of cancer. Bellan et al. (16) provided some data on this issue, but the data were not clearly presented and their conclusions are contradicted by other studies in the wider literature (1, 26) . There is considerable disagreement between studies as to what presenting features may suggest that further investigation is warranted.
Strengths and weaknesses of the study and in relation to other studies, discussing particularly any differences in results Whilst we took a systematic approach to identifying the literature relevant to the question of whether PMR is associated with cancer, our review still has a number of limitations. Primarily, it was difficult to decide how to specify our inclusion and exclusion criteria and to apply them in practice -specifically with regard to what to consider a research study and what to consider a case-series. We overcame this difficulty by adopting the approach of Ungprasert et al. (13) , and including only those papers with a comparator group without PMR in our formal review. However, in forming our conclusions, we have considered the wider literature, which included a number of sizable case series and case reports. Also of note is that of the three studies finding a significant association between PMR and cancer, two were the largest in the review by some way (15, 18) . Whilst the additional power provided by a larger study does not necessarily make this finding surprising, the post hoc power calculation provided by Muller et al. (15) suggests that this study has sufficient power to detect a relatively small hazard ratio of 1.2. However, even these large studies were not able to confidently suggest the types or sites of cancer likely to be associated with PMRlike symptoms.
Our systematic review excluded a large number of case reports and a number of case-series and case-control studies. Whilst it is difficult to make sense of the case report literature in a systematic way, there are some cancers that are frequently encountered in relation to PMR in this literature; leukaemias (24, (27) (28) (29) (30) , myelomas (30) (31) (32) (33) (34) (35) (36) , lymphomas (30, (37) (38) (39) (40) and lung cancer (41) (42) (43) (44) (45) . Whilst we know that there is likely to be substantial publication bias in relation to case reports, it is not known what impact this might have. For example, it may be that more cases are noted and published when they involved the immunerelated cancers known to be associated with other rheumatological conditions, such as rheumatoid arthritis and lymphoma, or it may be that these are less likely to be published in favour of cancers that have not previously been associated with rheumatological disorders. The types of cancer identified from the papers included in our systematic review are broadly similar to those that appear commonly in the literature. A recent review and case series concluded that PMR is not a paraneoplastic phenomenon and that the important thing was to conduct a rigorous diagnostic work-up before making the PMR diagnosis (1). This conclusion was based on a comparison of their clinical case series to studies in large databases, including those included in this review, specifically those by Ji et al. (18) and Muller et al. (15) . Whilst we agree that there is a clear need to fully assess a patient before making a diagnosis of PMR and that this should likely include screening for common cancers, it is worth noting that the comparison of cancer diagnosis rates made in this paper is flawed, as it compares absolute to relative rates, and that the rates of cancer diagnoses are not as high in other cohorts as the authors suggest.
Meaning of the study: possible mechanisms and implications for clinicians or policymakers
This study suggests that there is evidence of a short-term (<12 months) association between PMR and an underlying malignancy, o n l y such as rheumatoid arthritis and lympho ma, or it may be that these are less likely to o n l y ma, or it may be that these are less likely to although there is insufficient evidence to label this as truly paraneoplastic. Given the non-specific nature of common PMR symptoms, such as shoulder and hip girdle pain and stiffness, fatigue and weight loss, which may also occur in patients with malignancy, establishing a definitive paraneoplastic diagnosis may be challenging. Some of these symptoms may be mediated by cytokine release such as IL-6 and VEGF, which may occur in both conditions (6, 7) . These findings support the guideline suggestions regarding excluding cancer, suggesting that relative simple, economic tests such as a chest X-ray in a smoker, or a prostate specific antigen (PSA) may be warranted as part of the diagnostic work up of PMR. However, the relative lack of association of specific cancers suggests that more complex and costly investigations are not indicated for all patients. Clinicians however should be mindful of this PMRcancer association and consider additional investigations for a potential malignancy. However, we were unable to find convincing evidence as to which patients may be at highest risk of having a malignancy underlying their PMR symptoms.
Unanswered questions and future research
Despite a number of large studies and a systematic review and meta-analysis, there is not the evidence to suggest that PMR fulfils strict criteria as a paraneoplastic syndrome, particularly given the lack of evidence of improvement with treatment of the malignancy. However, although not truly paraneoplastic, there does appear to be a short-term association between PMR-like symptoms and malignancy. It would therefore seem prudent for future work to concentrate on identifying those patients presenting with PMR-like symptoms who are most likely to experience a cancer diagnosis in the shortterm and to attempt to elucidate the cancers most likely to be associated with a PMRlike presentation. This would better enable clinicians to target specific cancer screening in a clinical and cost effective manner to those most likely to benefit, during diagnostic work up.
n CONCLUSIONS
In reality, except for intellectual curiosity, it is probably immaterial whether PMR represents a true paraneoplastic syndrome, or if it is just that the early symptoms of some cancers are difficult to distinguish from true PMR. What matters is that the correct diagnosis is made early, so that appropriate treatment can be initiated. With this in mind, we suggest that when PMR is the suspected, or even obvious diagnosis, extra care is taken to assess whether the symptoms could be caused by an as yet unrecognised malignancy. Whilst there is limited evidence of specific malignancies that may be most prone to present in a similar way to PMR, we suggest consideration of prostate, haematological and lung cancers and lymphomas. Given the risk of cancer up to 12 months post PMR diagnosis, clinicians should maintain a high index of suspicion in PMR patients, especially in those who fail to respond to treatment or whose clinical appearance changes in some other way. 
